Advanced drug research and development of hepatitis B and HCC and data of easl2020 atzumab combined with bevacizumab

At the 2020 European Conference on liver research, researchers in the field of liver diseases from all over the world presented data on the safety and effectiveness of treatment for new patients with advanced hepatocellular carcinoma. At the same time, the safety results of three different new therapies for advanced or unresectable HCC were given, which is expected to become a new choice for patients with poor prognosis. At EASL 2020, researchers pointed out that in the past 10 years, the development of systematic treatment drugs for advanced liver cancer is mostly limited to a single choice. However, the research results of sorafenib and other new therapeutic drugs show that some new drugs developed for the treatment of advanced liver cancer can significantly improve the quality of life of patients who are difficult to treat in the past. On August 28, 2020, three research groups submitted safety and efficacy data to provide newly developed drugs for patients with advanced or unresectable liver cancer. Liver cancer is the second leading cause of cancer death in the world, accounting for more than 90% of primary liver cancer. About 90% of liver cancer is associated with a wide range of risk factors, such as chronic hepatitis B or hepatitis C infection, nonalcoholic fatty liver disease, alcohol intake and aflatoxin exposure. The prognosis of patients with HCC is still very poor. For example, in Europe, the 3-year survival rate of patients diagnosed with HCC at any stage under monitoring is estimated to be 47.3%, while the 3-year survival rate of patients diagnosed with HCC without monitoring is as low as 21.8%. < / P > < p > however, in recent years, more and more newly developed drugs for patients with advanced liver cancer have entered the clinical trial stage, which is expected to improve this prospect. Imbrave150 research, which has been published in the 2020 European liver academic annual meeting, is now published in four major medical journals around the world. It studies the combined application of atrazumab and bevacizumab with standard systemic therapy sorafenib. < / P > < p > in this 2-times-a-day, randomized, open trial, patients with unresectable liver cancer who did not receive systemic therapy received 1200 mg of intravenous atzumab + 15 mg / kg of intravenous bevacizumab or 400 mg of sorafenib. The researchers pointed out that the improvement of overall survival rate and progression free survival rate of these new drugs for advanced liver cancer has been reported in this trial. The median treatment time was 7.4 months for atzumab, 6.9 months for bevacizumab and 2.8 months for sorafenib. < / P > < p > grade 3-4 adverse events were reported in 57% of the subjects treated with etizol + bevacizumab and in those treated with sorafenib. The most serious grade 5 adverse reactions were 5% and 6%, respectively. There were more patients in the combination group than in the combination group. The incidence of immune mediated hepatitis is comparable between the 2 treatments, and the incidence rate of adverse events which is of special concern is similar and mostly mild. < / P > < p > Professor Michel Ducreux from Gustav Rousse cancer center in France commented on the above new drug development for advanced liver cancer: “the combination of atzumab and bevacizumab is generally well tolerated, and the adverse events caused by the combination of atzumab and bevacizumab can be controlled. Combined with the previous efficacy endpoints, the data released by the European liver Congress show that atzumab + bevacizumab should be regarded as the new standard of care for patients with unresectable liver cancer who have not received systematic treatment. ” < / P > < p > Xiaofan health conclusion: the above research data and conclusions were published at the 2020 European Conference on liver research by Richard Finn, Michel ducrux and Bruno Sangro. Among them, Michel ducrux also received the clinical trial funds from Roche, Merck, Bayer and cassettes; Bruno Sangro received subsidies from Bristol Myers Squibb and sirtex medical. This article mainly introduces the new safety and efficacy data of hepatocellular carcinoma, bringing hope for patients with advanced HCC, published in easl2020 on August 28, 2020. HEALTHY LIFE